FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080624651> ?p ?o ?g. }

• W2080624651 endingPage "998" @default.
• W2080624651 startingPage "989" @default.
• W2080624651 abstract "The epidermal growth factor receptor (EGFR) and ERBB2 (HER2) pathways and vascular endothelial growth factor (VEGF)-dependent angiogenesis have a pivotal role in cancer pathogenesis and progression. Robust experimental evidence has shown that these pathways are functionally linked and implicated in acquired resistance to targeted therapies making them attractive candidates for joined targeting. We undertook this phase I trial to assess the safety, the recommended dose for phase II trials (RPTD), pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary antitumour activity of the combination of lapatinib and sorafenib in patients with advanced refractory solid tumours.Four cohorts of at least three patients each received lapatinib once daily and sorafenib twice daily together on a continuous schedule. Doses of lapatinib and sorafenib were escalated based on dose-limiting toxicities (DLTs) in the first treatment cycle following a traditional 3+3 design until the RPTD was reached. Additional patients were treated at the RPTD to characterise PK profiles of this combination and to investigate the potential interaction between lapatinib and sorafenib. Serum samples were collected at baseline and then prospectively every two cycles to assess changes in PD parameters. This trial is registered with ClinicalTrials.gov, number NCT00984425.Thirty patients with advanced refractory solid tumours were enroled. DLTs were grade three fatigue and grade 3 atypical skin rash observed at dose levels 3 and 4, respectively. The higher dose level explored (lapatinib 1250mg/day and sorafenib 400mg twice daily) represented the RPTD of the combination. The most common drug-related adverse events were fatigue (68%), hypocalcemia (61%), diarrhoea (57%), lymphopaenia (54%), anorexia (50%), rash (50%), and hypophosphatemia (46%). PK analysis revealed no significant effect of sorafenib on the PK profile of lapatinib. Of the 27 assessable patients for clinical activity, one achieved a confirmed complete response, four (15%) had a partial response, and 12 (44%) achieved disease stabilisation. The disease control rate overall was 63%.Combination treatment with lapatinib and sorafenib was feasible with promising clinical activity and without significant PK interactions. Long term tolerability seems to be challenging." @default.
• W2080624651 created "2016-06-24" @default.
• W2080624651 creator A5012295180 @default.
• W2080624651 creator A5013442681 @default.
• W2080624651 creator A5019723028 @default.
• W2080624651 creator A5020949898 @default.
• W2080624651 creator A5021465650 @default.
• W2080624651 creator A5024344441 @default.
• W2080624651 creator A5024786689 @default.
• W2080624651 creator A5026852720 @default.
• W2080624651 creator A5041255789 @default.
• W2080624651 creator A5059424755 @default.
• W2080624651 creator A5062532607 @default.
• W2080624651 creator A5065803904 @default.
• W2080624651 creator A5070315144 @default.
• W2080624651 creator A5070833456 @default.
• W2080624651 creator A5074349466 @default.
• W2080624651 creator A5080694829 @default.
• W2080624651 creator A5082045927 @default.
• W2080624651 creator A5082515771 @default.
• W2080624651 date "2013-03-01" @default.
• W2080624651 modified "2023-10-16" @default.
• W2080624651 title "Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors" @default.
• W2080624651 cites W1971837077 @default.
• W2080624651 cites W1975540355 @default.
• W2080624651 cites W1999966467 @default.
• W2080624651 cites W2002226820 @default.
• W2080624651 cites W2002812414 @default.
• W2080624651 cites W2012915718 @default.
• W2080624651 cites W2013335792 @default.
• W2080624651 cites W2014881369 @default.
• W2080624651 cites W2024145840 @default.
• W2080624651 cites W2029637911 @default.
• W2080624651 cites W2034682639 @default.
• W2080624651 cites W2044468942 @default.
• W2080624651 cites W2053439872 @default.
• W2080624651 cites W2062756148 @default.
• W2080624651 cites W2081747183 @default.
• W2080624651 cites W2091463916 @default.
• W2080624651 cites W2097698108 @default.
• W2080624651 cites W2098884036 @default.
• W2080624651 cites W2100066495 @default.
• W2080624651 cites W2102942095 @default.
• W2080624651 cites W2104721463 @default.
• W2080624651 cites W2106656437 @default.
• W2080624651 cites W2110444464 @default.
• W2080624651 cites W2116177733 @default.
• W2080624651 cites W2147094816 @default.
• W2080624651 cites W2150740687 @default.
• W2080624651 cites W2170655985 @default.
• W2080624651 cites W2171406886 @default.
• W2080624651 cites W4252851641 @default.
• W2080624651 doi "https://doi.org/10.1016/j.ejca.2012.10.016" @default.
• W2080624651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23146956" @default.
• W2080624651 hasPublicationYear "2013" @default.
• W2080624651 type Work @default.
• W2080624651 sameAs 2080624651 @default.
• W2080624651 citedByCount "12" @default.
• W2080624651 countsByYear W20806246512013 @default.
• W2080624651 countsByYear W20806246512014 @default.
• W2080624651 countsByYear W20806246512015 @default.
• W2080624651 countsByYear W20806246512017 @default.
• W2080624651 countsByYear W20806246512020 @default.
• W2080624651 countsByYear W20806246512021 @default.
• W2080624651 crossrefType "journal-article" @default.
• W2080624651 hasAuthorship W2080624651A5012295180 @default.
• W2080624651 hasAuthorship W2080624651A5013442681 @default.
• W2080624651 hasAuthorship W2080624651A5019723028 @default.
• W2080624651 hasAuthorship W2080624651A5020949898 @default.
• W2080624651 hasAuthorship W2080624651A5021465650 @default.
• W2080624651 hasAuthorship W2080624651A5024344441 @default.
• W2080624651 hasAuthorship W2080624651A5024786689 @default.
• W2080624651 hasAuthorship W2080624651A5026852720 @default.
• W2080624651 hasAuthorship W2080624651A5041255789 @default.
• W2080624651 hasAuthorship W2080624651A5059424755 @default.
• W2080624651 hasAuthorship W2080624651A5062532607 @default.
• W2080624651 hasAuthorship W2080624651A5065803904 @default.
• W2080624651 hasAuthorship W2080624651A5070315144 @default.
• W2080624651 hasAuthorship W2080624651A5070833456 @default.
• W2080624651 hasAuthorship W2080624651A5074349466 @default.
• W2080624651 hasAuthorship W2080624651A5080694829 @default.
• W2080624651 hasAuthorship W2080624651A5082045927 @default.
• W2080624651 hasAuthorship W2080624651A5082515771 @default.
• W2080624651 hasConcept C111113717 @default.
• W2080624651 hasConcept C112705442 @default.
• W2080624651 hasConcept C121332964 @default.
• W2080624651 hasConcept C121608353 @default.
• W2080624651 hasConcept C126322002 @default.
• W2080624651 hasConcept C142424586 @default.
• W2080624651 hasConcept C143998085 @default.
• W2080624651 hasConcept C197934379 @default.
• W2080624651 hasConcept C2777329042 @default.
• W2080624651 hasConcept C2778019345 @default.
• W2080624651 hasConcept C2778570526 @default.
• W2080624651 hasConcept C2778695046 @default.
• W2080624651 hasConcept C2779438470 @default.
• W2080624651 hasConcept C2779786085 @default.
• W2080624651 hasConcept C530470458 @default.

• next